Premium
Vascular endothelial growth factor: A potential target of therapy in neuromyelitis optica?
Author(s) -
Yamamura Takashi
Publication year - 2015
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12258
Subject(s) - neuromyelitis optica , medicine , vascular endothelial growth factor , bevacizumab , antibody , vegf receptors , immunology , chemotherapy
An open study was conducted to evaluate the safety of bevacizumab, anti‐vascular endothelial growth factor antibody, in patients with neuromyelitis optica developing signs of relapse.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom